Is ADMA Biologics (ADMA) Attractive After Recent Share Price Swings And DCF Upside?
- If you are wondering whether ADMA Biologics at around US$16.38 is offering fair value or an opportunity, you are in the right place to unpack what the current price actually reflects.
- The stock has had a mixed run, with a 5.5% gain over the last 7 days, a 5.3% decline over the past 30 days, and an 8.4% decline year to date, following a very large 3-year return and around 7x over 5 years.
- Recent coverage has focused on ADMA Biologics as a listed plasma based biopharmaceutical company, with investors paying attention to how its commercial portfolio and production capabilities fit into the wider immunology and infectious disease space. That context helps explain why the share price can react sharply when sentiment around its products,…
Source link
